logo
  

Barclays Bank UK To Buy Kensington Mortgage, Certain Portfolio Of UK Mortgages In £2.3 Bln Deal

Banking major Barclays plc (BARC,BCS) announced Friday that Barclays Bank UK PLC has agreed to acquire UK specialist mortgage lender Kensington Mortgage Co. Ltd.

Barclays Bank UK is acquiring the business from companies controlled by funds managed by Blackstone Tactical Opportunities Advisors L.L.C. and funds affiliated with Sixth Street Partners LLC.

Barclays Bank UK has also agreed to acquire a portfolio of UK mortgages consisting primarily of mortgages originated by KMC from October 2021 to completion of the acquisition of KMC.

The total consideration payable by Barclays Bank UK under the deal agreements is expected to be approximately 2.3 billion pounds. The consideration assumes completion of the deal occurs at the beginning of December 2022 and the KMC Mortgage Portfolio comprises approximately 2.0 billion pounds of loans at that date.

The Transaction is subject to regulatory approval and is expected to complete in late fourth quarter or early first quarter, 2023.

Kensington Mortgage provides mortgages via brokers to borrowers with complex incomes. The business has approximately 600 employees and also services mortgages for other parties. KMC generated 65.9 million pounds of income and a pre-tax profit of 0.5 million pounds in the year 2021.

Barclays expects the acquisition to enable it to broaden its product offering and capabilities in the UK mortgage market, extend the number of customers and grow mortgage originations to better utilise strong UK funding base.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Longmont Colorado -based Royal Crest Dairy is recalling 2% Chocolate Milk citing the potential to be contaminated with undeclared egg, a known allergen, the U.S. Food and Drug Administration said. The recall involves Farmer's 2% Reduced Fat Chocolate Milk Pints with the code date of AUG-22. ANI Pharmaceuticals, Inc. (ANIP) Monday announced a wider loss for the second quarter, despite a 52 percent surge in revenues. For the full year 2022, the company reiterated the adjusted earnings per share range, revenue guidance and raised Cortrophin revenue outlook. The company reported a quarterly... Shares of BioNTech SE were losing around 4 percent in the morning trading in Germany and around 5 percent in the pre-market activity on Nasdaq after the German Covid-19 vaccine maker reported sharp drop in profit and revenues for the second quarter. However, the company recorded strong growth in first-half results. Further, the company maintained BioNTech COVID-19 vaccine revenue guidance
Follow RTT